On initial post‐treatment cystoscopy, one patient (20%) from the re‐induction BCG group had HGT1 with CIS recurrence, and two patients (18%) from the Gem/Doce group had HGTa recurrence. Here, SLC25A16 is linked to in situ carcinoma.